Teva Pharma (TEVA) Tops Q3 EPS by 7c; Boosts FY15 EPS Outlook

Teva Pharma (NYSE: TEVA) reported Q3 EPS of $1.35, $0.07 better than the analyst estimate of $1.28. Revenue for the quarter came in at $4.8 billion versus the consensus estimate of $4.75 billion.

Teva Pharma sees FY2015 EPS of $5.40-$5.45, versus prior guidance of $5.15-$5.40 and the consensus of $5.32.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Bernstein SocGen Group Upgrades X-Fab Silicon Foundries SE (XFAB:FP) to Outperform